Search Results - "AJANA, Faiza"

Clinical and virological features of acute hepatitis A during an ongoing outbreak among men who have sex with men in the North of France by Boucher, Anne, Meybeck, Agnes, Alidjinou, Kazali, Huleux, Thomas, Viget, Nathalie, Baclet, Veronique, Valette, Michel, Alcaraz, Isabelle, Sauser, Eveline, Bocket, Laurence, Faiza, Ajana

“…Since February 2017, an increase of acute hepatitis A (AHA) cases has been notified in North of France. We aimed to report clinical and virological features of…”
Get more information

Very slow decline of hepatitis B virus surface antigen and core related antigen in chronic hepatitis B patients successfully treated with nucleos(t)ide analogues by Alidjinou, Enagnon K., Michel, Charlotte, Canva, Valérie, Ajana, Faïza, Hober, Didier, Bocket, Laurence

“…We investigated the decline of hepatitis B virus surface antigen (HBsAg) and core related antigen (HBcrAg) in chronic hepatitis B patients sussessfully treated…”
Get full text

Brief Report: Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Females Living With HIV: An Integrated Analysis of 5 Trials by Orkin, Chloe, Ajana, Faiza, Kityo, Cissy, Koenig, Ellen, Natukunda, Eva, Gandhi-Patel, Bhumi, Wang, Hui, Liu, Yapei, Wei, Xuelian, White, Kirsten, Makadzange, Tariro, Pikora, Cheryl, McNicholl, Ian, Collins, Sean E., Brainard, Diana, Chuck, Susan K.

“…We characterized the efficacy and safety of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in a broad population of…”
Get full text

Clinical impact of tropism testing in a real-life cohort of HIV infected patients: a retrospective observational study by Deconinck, Laurène, Robineau, Olivier, Valette, Michel, Choisy, Philippe, Bocket, Laurence, Meybeck, Agnes, Ajana, Faiza

“…The circumstances of prescription of tropism tests clinically relevant in treatment-experienced patients are unclear. We performed a monocentric retrospective…”
Get full text

History of COVID-19 Symptoms and Seroprevalence of SARS-CoV-2 Antibodies in HIV-Infected Patients in Northern France after the First Wave of the Pandemic by Meybeck, Agnès, Huleux, Thomas, Tétart, Macha, Thill, Pauline, Derdour, Vincent, Bocket, Laurence, Alidjinou, Enagnon Kazali, Patoz, Pierre, Robineau, Olivier, Ajana, Faiza

“…To assess the prevalence of COVID-19 in people living with HIV (PLWHIV), we performed an epidemiological survey from 1 April through 1 August 2020 in an HIV…”
Get full text

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study by van Wyk, Jean, Ajana, Faïza, Bisshop, Fiona, De Wit, Stéphane, Osiyemi, Olayemi, Portilla Sogorb, Joaquín, Routy, Jean-Pierre, Wyen, Christoph, Ait-Khaled, Mounir, Nascimento, Maria Claudia, Pappa, Keith A, Wang, Ruolan, Wright, Jonathan, Tenorio, Allan R, Wynne, Brian, Aboud, Michael, Gartland, Martin J, Smith, Kimberly Y

“…Abstract Background The 2-drug regimen dolutegravir (DTG) + lamivudine (3TC) is indicated for treatment-naive adults with human immunodeficiency virus type 1…”
Get full text

Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial by Osiyemi, Olayemi, De Wit, Stéphane, Ajana, Faïza, Bisshop, Fiona, Portilla, Joaquín, Routy, Jean Pierre, Wyen, Christoph, Ait-Khaled, Mounir, Leone, Peter, Pappa, Keith A, Wang, Ruolan, Wright, Jonathan, George, Nisha, Wynne, Brian, Aboud, Michael, van Wyk, Jean, Smith, Kimberly Y

“…Abstract Background Switching to dolutegravir/lamivudine (DTG/3TC) was noninferior to continuing tenofovir alafenamide (TAF)–based regimens for maintaining…”
Get full text

Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study by van Wyk, Jean, Ait-Khaled, Mounir, Santos, Jesus, Scholten, Stefan, Wohlfeiler, Michael, Ajana, Faïza, Jones, Bryn, Nascimento, Maria-Claudia, Tenorio, Allan R., Smith, Don E., Wright, Jonathan, Wynne, Brian

Get full text

Reduced bone mineral density among HIV-infected, virologically controlled young men: prevalence and associated factors by Shaiykova, Arnoo, Pasquet, Armelle, Goujard, Cécile, Lion, Georges, Durand, Emmanuel, Bayan, Tatiana, Lachâtre, Marie, Choisy, Philippe, Ajana, Faïza, Bourdic, Katia, Viget, Nathalie, Riff, Bertrand, Quertainmont, Yann, Cortet, Bernard, Boufassa, Faroudy, Chéret, Antoine

“…OBJECTIVE:Reduced bone mineral density (BMD) is a frequent comorbidity observed in people living with HIV (PLHIV). We aimed to determine the prevalence of…”
Get full text

Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study by Jaeger, Hans, Overton, Edgar T, Richmond, Gary, Rizzardini, Giuliano, Andrade-Villanueva, Jaime Federico, Mngqibisa, Rosie, Hermida, Antonio Ocampo, Thalme, Anders, Belonosova, Elena, Ajana, Faïza, Benn, Paul D, Wang, Yuanyuan, Hudson, Krischan J, Español, Carlos Martín, Ford, Susan L, Crauwels, Herta, Margolis, David A, Talarico, Christine L, Smith, Kimberly Y, van Eygen, Veerle, Van Solingen-Ristea, Rodica, Vanveggel, Simon, Spreen, William R

“…Long-acting cabotegravir and rilpivirine administered monthly or every 2 months might address the challenges associated with daily oral antiretroviral therapy…”
Get full text

Once-daily dolutegravir versus darunavir plus cobicistat in adults at the time of primary HIV-1 infection: the OPTIPRIM2-ANRS 169 randomized, open-label, Phase 3 trial by Chéret, Antoine, Bauer, Rebecca, Meiffrédy, Vincent, Lopez, Pauline, Ajana, Faïza, Lacombe, Karine, Morlat, Philippe, Lascoux, Caroline, Reynes, Jacques, Calin, Ruxandra, Abel, Sylvie, Goujard, Cécile, Rouzioux, Christine, Avettand-Fenoel, Véronique, Meyer, Laurence

“…Abstract Background Whether integrase strand transfer inhibitors (INSTIs) can decrease HIV-1 DNA levels more rapidly than boosted PIs during primary HIV-1…”
Get full text

HIV and hypogonadism: a new challenge for young-aged and middle-aged men on effective antiretroviral therapy by Lachâtre, Marie, Pasquet, Armelle, Ajana, Faïza, Soudan, Benoit, Lion, Georges, Bocket, Laurence, Cornavin, Pauline, Senneville, Eric, Boufassa, Faroudy, Chéret, Antoine

“…Male hypogonadism is poorly defined in people living with HIV. Using a reliable free-testosterone assay, we examined the prevalence and risk factors of male…”
Get full text

Hypogonadism: a neglected comorbidity in young and middle-aged HIV-positive men on effective combination antiretroviral therapy by Lachâtre, Marie, Pasquet, Armelle, Ajana, Faïza, Soudan, Benoit, Quertainmont, Yann, Lion, Georges, Durand, Emmanuel, Bocket, Laurence, Mole, Martine, Cornavin, Pauline, Catalan, Pilartxo, Senneville, Éric, Goujard, Cécile, Boufassa, Faroudy, Cheret, Antoine

“…Objective: Male hypogonadism is poorly characterized in young-to-middle-aged people with HIV (PWH). We used a reliable free testosterone assay to assess the…”
Get full text

Brief Report: Improvement in Metabolic Health Parameters at Week 48 After Switching From a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen to the 2-Drug Regimen of Dolutegravir/Lamivudine: The TANGO Study by van Wyk, Jean, Ait-Khaled, Mounir, Santos, Jesus, Scholten, Stefan, Wohlfeiler, Michael, Ajana, Faïza, Jones, Bryn, Nascimento, Maria-Claudia, Tenorio, Allan R., Smith, Don E., Wright, Jonathan, Wynne, Brian

“…In TANGO, switching to dolutegravir/lamivudine was noninferior at 48 weeks to continuing 3-/4-drug tenofovir alafenamide-based regimens in virologically…”
Get full text

Tenofovir disoproxil fumarate and emtricitabine maintenance strategy in virologically controlled adults with low HIV-1 DNA: 48 week results from a randomized, open-label, non-inferiority trial by Prazuck, Thierry, Verdon, Renaud, Le Moal, Gwenaël, Ajana, Faïza, Bernard, Louis, Sunder, Simon, Roncato-Saberan, Mariam, Ponscarme, Diane, Etienne, Manuel, Viard, Jean-Paul, Pasdeloup, Thierry, Darasteanu, Iuliana, Pialoux, Gilles, de la Blanchardière, Arnaud, Avettand-Fènoël, Véronique, Parienti, Jean-Jacques, Hocqueloux, Laurent

“…Abstract Objectives Low HIV reservoirs may be associated with viral suppression under a lower number of antiretroviral drugs. We investigated tenofovir…”
Get full text

Thymidine analogue mutations in antiretroviral-naive HIV-1 patients on triple therapy including either zidovudine or stavudine by Bocket, Laurence, Yazdanpanah, Yazdan, Ajana, Faïza, Gerard, Yann, Viget, Nathalie, Goffard, Anne, Alcaraz, Isabelle, Wattré, Pierre, Mouton, Yves

“…Aims: The aims of this study were to: (i) determine the incidence of thymidine-associated mutations (TAMs) in an observational clinical cohort of naive HIV-1…”
Get full text

Severe toxoplasmosis imported from tropical Africa in immunocompetent patients: A case series by Leroy, Jordan, Houzé, Sandrine, Dardé, Marie-Laure, Yéra, Hélène, Rossi, Benjamin, Delhaes, Laurence, Gabriel, Frédéric, Loubet, Paul, Deleplancque, Anne-Sophie, Senneville, Eric, Ajana, Faïza, Sendid, Boualem, Malvy, Denis

“…Toxoplasmosis is a zoonosis caused by the protozoan Toxoplasma gondii. In immunocompetent patients the infection is usually benign. However, cases of severe…”
Get full text

Chagas disease, France by Lescure, François-Xavier, Canestri, Ana, Melliez, Hugues, Jauréguiberry, Stéphane, Develoux, Michel, Dorent, Richard, Guiard-Schmid, Jean-Baptiste, Bonnard, Philippe, Ajana, Faïza, Rolla, Valeria, Carlier, Yves, Gay, Frederick, Elghouzzi, Marie-Hélène, Danis, Martin, Pialoux, Gilles

“…Chagas disease (CD) is endemic to Latin America; its prevalence is highest in Bolivia. CD is sometimes seen in the United States and Canada among migrants from…”
Get full text

MUDANÇA PARA DTG/3TC EM COMBINAÇÃO DE DOSE FIXA FOI NÃO‐INFERIOR À CONTINUIDADE DE ESQUEMA BASEADO EM TAF (TBR) NA MANUTENÇÃO DA SUPRESSÃO VIRAL POR 96 SEMANAS (ESTUDO TANGO) by Wyk, Jean Van, Ajana, Faïza, Bisshop, Fiona, de Wit, Stéphane, Ait‐Khaled, Mounir, Wang, Ruolan, Wright, Jonathan, Aboud, Michael, Smith, Kimberly, Zajdenverg, Roberto

Get full text

Acute toxoplasmosis in an immunocompetent traveller to Senegal by Gachet, Benoit, Elbaz, Alexandre, Boucher, Anne, Robineau, Olivier, Fréalle, Emilie, Ajana, Faïza, Delannoy, Pierre-Yves, Thellier, Damien, Boussekey, Nicolas, Meybeck, Agnès, Senneville, Eric

Get full text